智通财经APP获悉，泰格医药(03347)绩后跌超3%，截至发稿，跌2.45%，报25.95港元，成交6050.58万港元。
消息面上，4月28日，泰格医药发布公告，于2025年第一季度，该集团取得营业收入15.64亿元，同比减少5.79%;归属于上市公司股东的净利润1.65亿元，同比减少29.61%;基本每股收益0.19元。
浙商证券此前指出，展望2025年看，认为大临床业务基数影响和调减影响均为一次性影响，伴随着订单执行、订单价格企稳，公司大临床毛利率仍有望回归到较高水平。此外，公司SMO业务较佳的订单支撑和效率优化下，毛利率水平仍有提升空间，实验室服务伴随着产能利用率爬坡，有望逐渐提升。考虑到公司作为本土临床CRO龙头，龙头壁垒持续体现，同时考虑到公司国际化有望进入加速阶段。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.